DelveInsight’s, “Interstitial Cystitis Pipeline Insight, 2023,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
For Interstitial Cystitis Emerging drugs, the Interstitial Cystitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Request for Sample Pages: Interstitial Cystitis Pipeline Assessment
Some of the key Interstitial Cystitis companies working in the market are:
• Merck & Co
• Teva Pharmaceutical Industries
• Integrative Therapeutics, Inc.
• Lipella Pharmaceuticals, Inc.
• Addex Therapeutics
• Seikagaku Corporation
• UCB
• Alivio Therapeutics
• Imbrium Therapeutics
• Ironwood Pharmaceuticals, And Many Others.
Learn more about the emerging Interstitial Cystitis pipeline therapies @ Interstitial Cystitis Clinical Trials
Interstitial cystitis Overview:
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of Interstitial cystitis may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. Interstitial cystitis can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men. However, more men may struggle with Interstitial cystitis than researchers originally thought.
Interstitial Cystitis Emerging Drugs
Certolizumab pegol: UCB
Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.
SI-722: Seikagaku Corporation
SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku’s proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.
Request a sample and discover the recent advances in Interstitial Cystitis treatment drugs @ Interstitial Cystitis Pipeline Report
Interstitial Cystitis Analytical Perspective by DelveInsight
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the Interstitial Cystitis pipeline report
Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ Interstitial Cystitis Drugs
Table of Content:
Introduction
Executive Summary
Interstitial Cystitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug name: Company name
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
LYT 503: PureTech Health
Inactive Products
Interstitial Cystitis Key Companies
Interstitial Cystitis Key Products
Interstitial Cystitis- Unmet Needs
Interstitial Cystitis- Market Drivers and Barriers
Interstitial Cystitis- Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Appendix
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting